These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 16785867

  • 1. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus.
    Dvorak CC, Callard E, Agarwal R.
    Bone Marrow Transplant; 2006 Aug; 38(3):253-4. PubMed ID: 16785867
    [No Abstract] [Full Text] [Related]

  • 2. Combination of Low-Dose, Short-Course Mycophenolate Mofetil With Cyclosporine and Methotrexate for Graft-Versus-Host Disease Prophylaxis in Allogeneic Stem Cell Transplant.
    Ramzi M, Haghighat S, Namdari N, Haghighinejad H.
    Exp Clin Transplant; 2021 Dec; 19(12):1328-1333. PubMed ID: 32778017
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW.
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Intraoral psoralen ultraviolet A irradiation (PUVA) treatment of refractory oral chronic graft-versus-host disease following allogeneic stem cell transplantation.
    Menillo SA, Goldberg SL, McKiernan P, Pecora AL.
    Bone Marrow Transplant; 2001 Oct; 28(8):807-8. PubMed ID: 11781637
    [No Abstract] [Full Text] [Related]

  • 9. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Maximizing the benefits of mycophenolate mofetil as graft-versus-host disease prophylaxis.
    Hamilton BK, Kalaycio M.
    Biol Blood Marrow Transplant; 2014 Nov; 20(11):1869-70. PubMed ID: 25065905
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Response to mycophenolate mofetil therapy in refractory chronic graft-versus-host disease.
    Busca A, Locatelli F, Marmont F, Audisio E, Falda M.
    Haematologica; 2003 Jul; 88(7):837-9. PubMed ID: 12857569
    [No Abstract] [Full Text] [Related]

  • 14. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities.
    Furlong T, Storb R, Anasetti C, Appelbaum FR, Deeg HJ, Doney K, Martin P, Sullivan K, Witherspoon R, Nash RA.
    Bone Marrow Transplant; 2000 Nov; 26(9):985-91. PubMed ID: 11100278
    [Abstract] [Full Text] [Related]

  • 15. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients.
    Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G, Garvin J, George D, Bradley MB, Wolownik K, Wischhover C, Levy J, Skerrett D, Cairo MS.
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):246-58. PubMed ID: 15077223
    [Abstract] [Full Text] [Related]

  • 16. Successful Second Allogeneic Stem Cell Transplantation From a Sibling Donor for Relapse of Myelodysplastic Syndrome in a Recipient of a Renal Transplant From His Mother: Case Report.
    Ikeda M, Tsukada N, Chikai H, Tasaki M, Saito K, Nakagawa Y, Takahashi K, Suzuki K.
    Transplant Proc; 2016 Nov; 48(9):3085-3087. PubMed ID: 27932152
    [Abstract] [Full Text] [Related]

  • 17. Revisiting mycophenolate mofetil for steroid-refractory acute graft-versus-host disease: Is higher dosing effective in children?
    Levine JE.
    Pediatr Transplant; 2015 Sep; 19(6):582-3. PubMed ID: 26215797
    [No Abstract] [Full Text] [Related]

  • 18. Mycophenolate mofetil (MMF) for refractory chronic graft versus host disease (cGvHD).
    Castagna L.
    Haematologica; 2003 Aug; 88(8):ELT28; author reply ELT29. PubMed ID: 12935991
    [No Abstract] [Full Text] [Related]

  • 19. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.